Plain-English translation of NCT05196035 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called finerenone can help children with chronic kidney disease better than their current treatment alone. The medication is given in addition to medicines your child may already be taking to manage kidney function and blood pressure. Researchers want to see if this combination approach can reduce the amount of protein leaking into your child's urine.
Many children with chronic kidney disease continue to lose protein in their urine even when taking standard kidney medicines. This study exists to find out whether this new treatment can provide extra protection for children's kidneys by working in a different way than their current medications.
Your child would participate for 6 months and receive either the new medication or a placebo (a pill with no medicine) in addition to their current kidney medicine — neither you nor the study team will know which one during the study. Your child will have regular visits where blood and urine samples are taken to check kidney function, blood pressure, and how the body is handling the medication. The dose of medication is adjusted based on your child's age and weight.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States